MAPT and Alzheimer disease: Importantly, future efforts to examine whether Rlip overexpression can reduce the cognitive dysfunction, mitochondrial aberrations, and synaptic deficits developed by transgenic APP and Tau mice may lead to novel therapeutic options for AD patients.